Novartis Unlocks Allergy Breakthrough: $2 Billion Acquisition Fuels Next-Gen Therapy
Novartis AG (NYSE:NVS) recently disclosed its intent to acquire Excellergy, a privately-held biotechnology company. Excellergy is engaged in developing innovat…
Novartis AG (NYSE:NVS) recently disclosed its intent to acquire Excellergy, a privately-held biotechnology company. Excellergy is engaged in developing innovative anti-IgE therapies designed to treat allergic diseases. The acquisition terms specify that Novartis will disburse up to US$2 billion, consisting of both an initial payment and subsequent payments contingent on performance milestones, for the acquisition of Excellergy.
Novartis AG (NYSE:NVS) currently holds a Ranked Stocks (RS) Score of 77.67, placing it in the 80.79th percentile within its country and sector. The stock demonstrates strength in Valuation (82.85) and Profitability (90.74). However, it shows weaker performance in Growth (58.83), Momentum (63.98), and EPS Revisions (64.00). Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.